Literature DB >> 2157567

Quantitative measurement of cytomegalovirus-specific IgG and IgM antibodies in relation to cytomegalovirus antigenaemia and disease activity in kidney recipients with an active cytomegalovirus infection.

M Van der Giessen1, A P van den Berg, W van der Bij, S Postma, W J van Son, T H The.   

Abstract

In a longitudinal investigation 103 kidney recipients were studied with respect to the development of cytomegalovirus (CMV) specific antibodies of the IgG and IgM class, in relation to the detection of CMV antigenaemia (immediate early antigen, IEA), in weekly obtained blood samples during the first 3 months after transplantation. In 15 out of 49 (31%) seronegative patients a primary infection occurred, which was characterized by a quick rise in IgM antibody followed by a slower production of IgG antibody, high maximum numbers of IEA+ cells, and a CMV syndrome in 11 patients. In 35 out of 54 (65%) seropositive patients a secondary infection occurred. After a post-operative fall in the IgG antibody, which was also found in patients without an active infection and which was accompanied by a similar drop in serum albumin and IgG, a second dip in IgG antibody was found 6 days before the first IEA+ leucocyte appeared in the blood. This was followed by a significant increase, indicative of an active immune response in consequence of the infection, 18 days later. In 31 of these 35 patients an IgM response was found. This could be ascribed to the presence of rheumatoid factor activity in 20 of them. Eight patients who showed a transient rise in IgG antibody between the two dips could be distinguished from the remaining ones by a lower maximum number of IEA+ cells and less severe disease symptoms. The described results suggest that (i) an adequate humoral immune system may prevent symptomatic CMV disease in secondary infections; and (ii) CMV-specific antibodies may be removed from the circulation by antigens present in infected tissues before CMV antigenaemia becomes detectable.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157567      PMCID: PMC1535214          DOI: 10.1111/j.1365-2249.1990.tb06441.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Cytomegalovirus (CMV) antigenemia: rapid diagnosis and relationship with CMV-associated clinical syndromes in renal allograft recipients.

Authors:  W van der Bij; W J van Son; A P van der Berg; A M Tegzess; R Torensma; T H The
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

2.  Detection of immunoglobulin M and G antibodies against cytomegalovirus early and late antigens by enzyme-linked immunosorbent assay.

Authors:  J M Middeldorp; J Jongsma; A ter Haar; J Schirm; T H The
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

3.  Antibody response to cytomegalovirus after renal transplantation: comparison of patients with primary and recurrent infections.

Authors:  R F Pass; P D Griffiths; A M August
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

4.  Antibody reactions to virus-specific early antigens (EA) in patients with cytomegalovirus (CMV) infection.

Authors:  T H The; G Klein; M M Langenhuysen
Journal:  Clin Exp Immunol       Date:  1974-01       Impact factor: 4.330

5.  Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections.

Authors:  S H Cheeseman; R H Rubin; J A Stewart; N E Tolkoff-Rubin; A B Cosimi; K Cantell; J Gilbert; S Winkle; J T Herrin; P H Black; P S Russell; M S Hirsch
Journal:  N Engl J Med       Date:  1979-06-14       Impact factor: 91.245

Review 6.  Cytomegalovirus infections following renal transplantation.

Authors:  J Glenn
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

7.  Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus.

Authors:  L Rasmussen; D Kelsall; R Nelson; W Carney; M Hirsch; D Winston; J Preiksaitis; T C Merigan
Journal:  J Infect Dis       Date:  1982-02       Impact factor: 5.226

8.  The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation.

Authors:  M L Smiley; C G Wlodaver; R A Grossman; C F Barker; L J Perloff; N B Tustin; S E Starr; S A Plotkin; H M Friedman
Journal:  Transplantation       Date:  1985-08       Impact factor: 4.939

9.  Direct enzyme-linked immunosorbent assay that uses peroxidase-labeled antigen for determination of immunoglobulin M antibody to cytomegalovirus.

Authors:  A M van Loon; F W Heessen; J T van der Logt; J van der Veen
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

10.  Cytolytic IgM antibody to cytomegalovirus in primary cytomegalovirus infection in humans.

Authors:  R F Betts; S G Schmidt
Journal:  J Infect Dis       Date:  1981-06       Impact factor: 5.226

View more
  12 in total

1.  Cytomegalovirus antigenemia assay.

Authors:  M van der Giessen; T H The; W J van Son
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

2.  Cytomegalovirus-specific antibodies to an immediate early antigen and a late membrane antigen and their possible role in controlling secondary cytomegalovirus infection.

Authors:  J van Zanten; M van der Giessen; L H van der Voort; W J van Son; W van der Bij; T H The
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

3.  Direct quantification of human cytomegalovirus immediate-early and late mRNA levels in blood of lung transplant recipients by competitive nucleic acid sequence-based amplification.

Authors:  A E Greijer; E A Verschuuren; M C Harmsen; C A Dekkers; H M Adriaanse; T H The; J M Middeldorp
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

4.  Coronary angioplasty induces rise in Chlamydia pneumoniae-specific antibodies.

Authors:  A Tiran; R A Tio; J M Ossewaarde; B Tiran; P den Heijer; T H The; M M Wilders-Truschnig
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

5.  Clinical significance of cytomegalovirus infection in patients with inflammatory bowel disease.

Authors:  Elena Garrido; Elisa Carrera; Rebeca Manzano; Antonio Lopez-Sanroman
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

6.  Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders.

Authors:  E Brouwer; J W Tervaert; G Horst; M G Huitema; M van der Giessen; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

7.  Humoral immune response to human cytomegalovirus in patients undergoing percutaneous transluminal coronary angioplasty.

Authors:  A Tiran; R A Tio; E Oostenveld; M C Harmsen; B Tiran; P Den Heijer; S H Monnink; M M Wilders-Truschnig; T H The
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

8.  Early serodiagnosis of acute human cytomegalovirus infection by enzyme-linked immunosorbent assay using recombinant antigens.

Authors:  R Vornhagen; B Plachter; W Hinderer; T H The; J Van Zanten; L Matter; C A Schmidt; H H Sonneborn; G Jahn
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

9.  The DNA-binding protein pUL57 of human cytomegalovirus is a major target antigen for the immunoglobulin M antibody response during acute infection.

Authors:  R Vornhagen; W Hinderer; H H Sonneborn; G Bein; L Matter; T H The; G Jahn; B Plachter
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

10.  Humoral immune response against human cytomegalovirus (HCMV)-specific proteins after HCMV infection in lung transplantation as detected with recombinant and naturally occurring proteins.

Authors:  J van Zanten; M C Harmsen; M van der Giessen; W van der Bij; J Prop; L de Leij; T H The
Journal:  Clin Diagn Lab Immunol       Date:  1995-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.